We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
HYPE3.SA

Price
19.37
Stock movement up
+0.03 (0.16%)
Company name
Hypera S.A
Exchange
(SA
,
Currency
BRL
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
12.26B
Ent value
22.70B
Price/Sales
1.58
Price/Book
1.00
Div yield
-
Div growth
-
Growth years
-
FCF payout
10.24%
Trailing P/E
7.81
Forward P/E
7.67
PEG
-
EPS growth
7.65%
1 year return
-37.03%
3 year return
-20.96%
5 year return
-7.91%
10 year return
1.09%
Last updated: 2025-04-12

DIVIDENDS

HYPE3.SA does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E7.81
Price to OCF6.09
Price to FCF9.50
Price to EBITDA4.66
EV to EBITDA8.63

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.58
Price to Book1.00
EV to Sales2.92

FINANCIALS

Per share

Loading...
Per share data
Current share count632.68M
EPS (TTM)2.47
FCF per share (TTM)2.03

Income statement

Loading...
Income statement data
Revenue (TTM)7.78B
Gross profit (TTM)4.66B
Operating income (TTM)2.25B
Net income (TTM)1.57B
EPS (TTM)2.47
EPS (1y forward)2.53

Margins

Loading...
Margins data
Gross margin (TTM)59.90%
Operating margin (TTM)28.92%
Profit margin (TTM)20.16%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash3.21B
Net receivables2.99B
Total current assets8.79B
Goodwill7.34B
Intangible assets4.34B
Property, plant and equipment3.73B
Total assets25.87B
Accounts payable766.07M
Short/Current long term debt10.74B
Total current liabilities4.85B
Total liabilities13.65B
Shareholder's equity12.22B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)2.01B
Capital expenditures (TTM)721.46M
Free cash flow (TTM)1.29B
Dividends paid (TTM)132.05M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity12.83%
Return on Assets6.06%
Return on Invested Capital6.83%
Cash Return on Invested Capital5.62%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open19.63
Daily high19.63
Daily low19.22
Daily Volume1.41M
All-time high50.81
1y analyst estimate31.26
Beta0.44
EPS (TTM)2.47
Dividend per share-
Ex-div date27 Mar 2025
Next earnings date-

Downside potential

Loading...
Downside potential data
HYPE3.SAS&P500
Current price drop from All-time high-61.88%-12.89%
Highest price drop-74.64%-56.47%
Date of highest drop23 Nov 20119 Mar 2009
Avg drop from high-27.24%-11.07%
Avg time to new high37 days12 days
Max time to new high1369 days1805 days
COMPANY DETAILS
HYPE3.SA (Hypera S.A) company logo
Marketcap
12.26B
Marketcap category
Large-cap
Description
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex " A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Employees
10301
Investor relations
-
CEO
Country
Brazil
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Hypera SA (HYPMY) reports significant product launches and sustainability accolades amidst revenue challenges and competitive pressures.
March 24, 2025
Hypera SA (HYPMY) reports robust sellout growth and significant free cash flow increase, while navigating competitive challenges and investing in innovation.
November 15, 2024
Hypera SA (HYPMY) reports robust financial performance with significant R&D investments, while navigating competitive pressures in the generics market.
October 9, 2024